PSMC4

Across TCGA pan-cancer cohorts, PSMC4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PSMC4 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PSMC4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PSMC4 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

LUAD, PDAC, and OV are the cancer types where PSMC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.609	0.888	<.001	17	view →
PDAC	DFS	Quartile	All	0.839	0.716	.020	6	view →
OV	DFS	Median	All	0.839	1.000	.015	4	view →
CCRCC	DFS	Tertile	III,IV	0.887	0.198	.024	3	view →
HNSC	DFS	Tertile	III,IV	0.926	0.719	.034	2	view →
LSCC	OS	Median	All	0.806	1.000	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PSMC4–LUAD (OS)

Open the LUAD breakdown →